The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study ...
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ...
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Semantic Scholar
Progression-free survival for palbociclib plus letrozole by line of... | Download Scientific Diagram
A) Kaplan–Meier curve of progression-free survival in patients who... | Download Scientific Diagram
Journal of Breast Disease
IJMS | Free Full-Text | Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind ...
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
Progression-free survival in the PALOMA-1 study (palbociclib +... | Download Scientific Diagram
Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2− Advanced/Metastatic Breast Cancer | In Vivo
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | Breast Cancer Research
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study - Ha - 2022 -
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Semantic Scholar
IBRANCE 75 mg hard capsules - Summary of Product Characteristics (SmPC) - (emc)
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 -
Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
IBRANCE® capsules (palbociclib) Clinical Studies | Pfizer Medical Information - US
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | Breast Cancer Research
Frontiers | Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer - Yi Li, Wei Li, Chengcheng Gong, Yabin Zheng, Quchang Ouyang,
Ibrance: Package Insert - Drugs.com
Cancers | Free Full-Text | Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
